Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1984 December; 77(12): 1023–1029.
PMCID: PMC1440179

Tumour immunology: a review.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Brickell PM, Latchman DS, Murphy D, Willison K, Rigby PW. Activation of a Qa/Tla class I major histocompatibility antigen gene is a general feature of oncogenesis in the mouse. Nature. 1983 Dec 22;306(5945):756–760. [PubMed]
  • FOLEY EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 1953 Dec;13(12):835–837. [PubMed]
  • Golstein P, Rubin B, Denizot F, Luciani MF. Xenoserum-induced cytolytic "T" cells: polyclonal specificity with an apparent "anti-self" component, and cooperative induction. Immunobiology. 1979 Aug;156(1-2):121–137. [PubMed]
  • Greaves MF. Analysis of the clinical and biological significance of lymphoid phenotypes in acute leukemia. Cancer Res. 1981 Nov;41(11 Pt 2):4752–4766. [PubMed]
  • Harris H. The carapace of the cancer cell. The Osler oration 1984. J R Coll Physicians Lond. 1984 Jul;18(3):161–165. [PubMed]
  • Hellström KE, Hellström I. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol. 1974;18:209–277. [PubMed]
  • Kärre K, Klein GO, Kiessling R, Klein G, Roder JC. Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature. 1980 Apr 17;284(5757):624–626. [PubMed]
  • Lennox ES, Lowe AD, Cohn J, Evan G. Specific antigens on methylcholanthrene-induced tumors of mice. Transplant Proc. 1981 Dec;13(4):1759–1761. [PubMed]
  • Medawar PB, Hunt R. Vulnerability of methylcholanthrene-induced tumours to immunity aroused by syngeneic foetal cells. Nature. 1978 Jan 12;271(5641):164–165. [PubMed]
  • Metcalfe S, Milner J, Svvennsen RJ. A new indicator of human malignant tumour. Br J Cancer. 1984 Mar;49(3):337–342. [PMC free article] [PubMed]
  • Moss DJ, Rickinson AB, Wallace LE, Epstein MA. Sequential appearance of Epstein-Barr virus nuclear and lymphocyte-detected membrane antigens in B cell transformation. Nature. 1981 Jun 25;291(5817):664–666. [PubMed]
  • Prehn RT. The immune reaction as a stimulator of tumor growth. Science. 1972 Apr 14;176(4031):170–171. [PubMed]
  • Rickinson A. Epstein-Barr virus in epithelium. Nature. 1984 Jul 12;310(5973):99–100. [PubMed]
  • Roder J, Duwe A. The beige mutation in the mouse selectively impairs natural killer cell function. Nature. 1979 Mar 29;278(5703):451–453. [PubMed]
  • Rojko JL, Olsen RG. The immunobiology of the feline leukemia virus. Vet Immunol Immunopathol. 1984 May;6(1-2):107–165. [PubMed]
  • Schlager SI, Ohanian SH, Borsos T. Correlation between the ability of tumor cells to resist humoral immune attack and their ability to synthesize lipid. J Immunol. 1978 Feb;120(2):463–471. [PubMed]
  • Terman DS, Yamamoto T, Mattioli M, Cook G, Tillquist R, Henry J, Poser R, Daskal Y. Extensive necrosis of spontaneous canine mammary adenocarcinoma after extracorporeal perfusion over Staphylococcus aureus Cowans I. I. Description of acute tumoricidal response: morphologic, histologic, immunohistochemical, immunologic, and serologic findings. J Immunol. 1980 Feb;124(2):795–805. [PubMed]
  • Vyakarnam A, Lachmann PJ, Sikora K. The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice. Immunology. 1981 Feb;42(2):337–348. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press